Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 9, 2014, Pages 837-848

  Yang, Guang ^a   Zhang, Shenghong ^b   Gao, Fei ^a   Liu, Zhenyin ^a   Lu, Mingjian ^a   Peng, Sheng ^a   Zhang, Tao ^a   Zhang, Fujun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer cells; HOTAIR; IRF1; Osteopontin

Indexed keywords

CANCER CELLS; HOTAIR; IRF1; OSTEOPONTIN;

ANIMALS; ANTIGENS, CD44; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; MICE; MICE, INBRED BALB C; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RNA, LONG NONCODING;

EID: 84904439740     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.06.020     Document Type: Article

References (36)

1. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
2. Chakraborty G., Jain S., Behera R., Ahmed M., Sharma P., Kumar V., Kundu G.C. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 2006, 6:819-830.
3. Denhardt D.T., Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993, 7:1475-1482.
4. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2302-2309.
5. Kale S., Raja R., Thorat D., Soundararajan G., Patil T.V., Kundu G.C. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Oncogene 2014, 33:2295-2306.
6. Hui E.P., Sung F.L., Yu B.K., Wong C.S., Ma B.B., Lin X., Chan A., Wong W.L., Chan A.T. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin. Cancer Res. 2008, 14:7080-7087.
7. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst. 2002, 94:513-521.
8. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., Hainaut P., Marrero J.A., Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490.
9. Huang J., Pan C., Hu H., Zheng S., Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One 2012, 7:e47901.
10. Song G., Cai Q.F., Mao Y.B., Ming Y.L., Bao S.D., Ouyang G.L. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci. 2008, 99:1901-1907.
11. Matusan-Ilijas K., Damante G., Fabbro D., Dordevic G., Hadzisejdic I., Grahovac M., Avirovic M., Grahovac B., Jonjic N., Lucin K. EGFR expression is linked to osteopontin and Nf-kappaB signaling in clear cell renal cell carcinoma. Clin. Transl. Oncol. 2013, 15:65-71.
12. Yoo B.K., Gredler R., Chen D., Santhekadur P.K., Fisher P.B., Sarkar D. c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF. J. Hepatol. 2011, 55:1317-1324.
13. Berge G., Pettersen S., Grotterod I., Bettum I.J., Boye K., Maelandsmo G.M. Osteopontin-an important downstream effector of S100A4-mediated invasion and metastasis. Int. J. Cancer 2011, 129:780-790.
14. Guttman M., Donaghey J., Carey B.W., Garber M., Grenier J.K., Munson G., Young G., Lucas A.B., Ach R., Bruhn L., Yang X., Amit I., Meissner A., Regev A., Rinn J.L., Root D.E., Lander E.S. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011, 477:295-300.
15. Khalil A.M., Guttman M., Huarte M., Garber M., Raj A., Rivea M.D., Thomas K., Presser A., Bernstein B.E., van Oudenaarden A., Regev A., Lander E.S., Rinn J.L. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11667-11672.
16. Rinn J.L., Kertesz M., Wang J.K., Squazzo S.L., Xu X., Brugmann S.A., Goodnough L.H., Helms J.A., Farnham P.J., Segal E., Chang H.Y. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007, 129:1311-1323.
17. Gupta R.A., Shah N., Wang K.C., Kim J., Horlings H.M., Wong D.J., Tsai M.C., Hung T., Argani P., Rinn J.L., Wang Y., Brzoska P., Kong B., Li R., West R.B., van de Vijver M.J., Sukumar S., Chang H.Y. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
18. Bhan A., Hussain I., Ansari K.I., Kasiri S., Bashyal A., Mandal S.S. Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J. Mol. Biol. 2013, 425:3707-3722.
19. Zhuang Y., Wang X., Nguyen H.T., Zhuo Y., Cui X., Fewell C., Flemington E.K., Shan B. Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen. J. Hematol. Oncol. 2013, 6:35.
20. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001, 19:623-655.
21. Chen F., Song J. Di J, Q. Zhang, H. Tian, J. Zheng, IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation. Tumour Biol. 2012, 33:2217-2225.
22. Hong S., Kim H.Y., Kim J., Ha H.T., Kim Y.M., Bae E., Kim T.H., Lee K.C., Kim S.J. Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. J. Biol. Chem. 2013, 288:3560-3570.
23. Piya S., Moon A.R., Song P.I., Hiscott J., Lin R., Seol D.W., Kim T.H. Suppression of IRF4 by IRF1, 3, and 7 in Noxa expression is a necessary event for IFN-gamma-mediated tumor elimination. Mol. Cancer Res. 2011, 9:1356-1365.
24. Fulda S., Debatin K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002, 21:2295-2308.
25. Yu Q., Vazquez R., Khojeini E.V., Patel C., Venkataramani R., Larson D.F. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H76-H85.
26. Lin Y.H., Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J. Biol. Chem. 2001, 276:46024-46030.
27. Robertson B.W., Bonsal L., Chellaiah M.A. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol. Cancer 2010, 9:260.
28. Dai J., Li B., Shi J., Peng L., Zhang D., Qian W., Hou S., Zhao L., Gao J., Cao Z., Zhao J., Wang H., Guo Y. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol. Immunother. 2010, 59:355-366.
29. Unni E., Kittrell F.S., Singh U., Sinha R. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res. 2004, 6:R586-R592.
30. Gutschner T., Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012, 9:703-719.
31. Yang F., Yi F., Zheng Z., Ling Z., Ding J., Guo J., Mao W., Wang X., Wang X., Ding X., Liang Z. Du Q, Characterization of a carcinogenesis-associated long non-coding RNA. RNA Biol. 2012, 9:110-116.
32. Shinohara M.L., Kim H.J., Kim J.H., Garcia V.A., Cantor H. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7235-7239.
33. Zohar R., Suzuki N., Suzuki K., Arora P., Glogauer M., McCulloch C.A., Sodek J. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell. Physiol. 2000, 184:118-130.
34. Park J., Kim K., Lee E.J., Seo Y.J., Lim S.N., Park K., Rho S.B., Lee S.H., Lee J.H. Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17028-17033.
35. Massimino M., Vigneri P., Fallica M., Fidilio A., Aloisi A., Frasca F., Manzella L. IRF5 promotes the proliferation of human thyroid cancer cells. Mol. Cancer 2012, 11:21.
36. Yanai H., Chen H.M., Inuzuka T., Kondo S., Mak T.W., Takaoka A., Honda K., Taniguchi T. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3402-3407.